Contacts

Abhinav K Jha, Ph.D.

CONTACT

314-273-2655 a.jha@wustl.edu

Sponsors

Lead Sponsor

Washington University School of Medicine

Collaborators

National Institute for Biomedical Imaging and Bioengineering (NIBIB)

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

No

Inclusion Criteria

•Histologically or cytologically confirmed castration-resistant prostate cancer with symptomatic bone metastases.
•Minimum detectable skeletal lesion count of 3.
•Eligible to receive Xofigo.
•At least 18 years of age.
•ECOG performance status ≤ 3.
•Ability to understand and willingness to sign an IRB-approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion Criteria

•Predominant visceral metastatic disease.
•Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial
•Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
•Concurrent alternative radiopharmaceuticals
•Inability to maintain stationary supine pose for 45-60 minutes
•Eligibility Criteria - Physicians:
•Medical Oncologist or Radiation Oncologist at Siteman Cancer Center.
•Treating patients with prostate cancer.
•Willing to complete Physician Questionnaire during participation.

Related studies

RECRUITINGPhase 3

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

NCT06274047 · Androgen Axis Suppression, Prostatectomy, and more

RECRUITINGPhase 1/2

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more

RECRUITINGPhase 1/2

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

NCT07226986 · PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

RECRUITINGNA

Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors

NCT07436078 · Female Breast Cancer, Prostate Cancer, and more

RECRUITINGPhase 2

The COSMYC Trial (COmbined Suppression of MYC)

NCT06922318 · Metastatic Castration-resistant Prostate Cancer

View all related studies →

Low-Count Quantitative SPECT for Men Treated With Radium-223

What this study is about

Save this trial guide to your notes

Contacts

Sponsors

Related studies

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors

The COSMYC Trial (COmbined Suppression of MYC)

Trial snapshot

Condition

Locations shown

For caregivers